Analysis for COR

📈 Growth & Financial Trajectory

Over 8 quarters, Revenues rose from about $67.1B (2024 Q4) to about $84.8B (2026 Q3), with a mid‑2026 dip to $78.4B. Net income expanded from about $7.5M to roughly $0.78B, including a quarterly peak near $1.63B in 2026Q2, signaling improving earnings power. Yet gross margins stay slender, near 4%, and operating margins linger around 1–2%, implying limited operating leverage to sustain material profitability gains.

💰 Margins & Cash Flow

Gross margin remains around 4–5% with modest margin expansion; operating income is positive but thin relative to revenue. Cash flow from operations has been mixed: several quarters strong (e.g., 2026Q3: $2.65B), but others negative (e.g., 2025Q2). Net cash flow mirrors this volatility, while investing cash flows are typically negative, pressuring free cash generation.

🛡️ Balance Sheet & Liquidity

Assets generally cover liabilities, but working capital is often negative: current assets around $55–58B vs current liabilities of $56–60B. Long‑term debt sits around $7–12B, with equity modest, suggesting leverage risk and liquidity sensitivity.

⚠️ Key Drivers & Risks

• Drivers: Healthcare/distribution demand; scale benefits in supply chain.
• Risks: Margin compression vs peers; cyclicality and sustained working capital/debt pressure.